Drug name: PG11047


Related CSCTT Targets

ERBB2 [ref.1]P04626

CGC11047, PG11047, SL11047

Cas.no PubChem ID
206991-64-2 9822383
Introduction
CGC11047 is a second generation polyamine analogue, synthesized through the restriction of molecular conformations of parent polyamine compounds, with potential antineoplastic activity. It may displace endogenous polyamines from DNA binding sites, thereby interfering with cell cycle processes dependent upon polyamine binding and function, and resulting in cell-cycle arrest, induction of apoptosis, depletion of polyamines, and interference with gene and ligand-receptor activities involved with cell growth. This agent may exhibit decreased toxicity and enhanced cytotoxicity profiles compared to first-generation polyamine compounds. In tumor cells, there is an increase dependence on polyamines as well as a dysregulated polyamine metabolic pathway resulting in abnormal or sustained tumor growth.

CGC11047, PG11047, SL11047-Structure

...

Reference

  • [1] Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047. Cirenajwis, H., et al. (2010).Anticancer Drugs.21(10):897-906.
    20838207. [ 20838207 ]

Back to top